Research on human papillomavirus (HPV) and related infections
Latest Research Highlights
From November 2025
Vaccinating girls aged 9-20 years with a single-dose HPV vaccine is the most efficient strategy for cervical cancer prevention in low-income countries (ref: Bénard doi.org/10.1016/S2214-109X(25)00376-6/).
HPV vaccination coverage among adults aged 27-45 years in the U.S. remains low at 2.7%, despite a slight increase (ref: Lu doi.org/10.1016/j.amepre.2025.108180/).
A nasal therapeutic HPV vaccine targeting HPV16 E7 shows promise in preventing cervical cancer (ref: Nakahashi-Ouchida doi.org/10.1126/scitranslmed.ado8840/).
HPV clearance was associated with increased HIV risk among women, particularly for high-risk HPV types (ref: Hathaway doi.org/10.1093/jnci/).
Low-intensity cervical screening for HPV-vaccinated women did not significantly increase the risk of high-grade lesions compared to high-intensity screening (ref: Ortega Llobet doi.org/10.1002/ijc.70229/).
Cultural stigma significantly impacts the uptake of cervical cancer prevention services in Nigeria (ref: Wapmuk doi.org/10.1136/bmjgh-2025-020065/).
The dual-CRISPR system achieved attomolar sensitivity for pathogen detection, offering a new perspective on HPV detection methodologies (ref: Su doi.org/10.1021/acs.analchem.5c05145/).